1. Home
  2. ACOG vs ALTS Comparison

ACOG vs ALTS Comparison

Compare ACOG & ALTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACOG
  • ALTS
  • Stock Information
  • Founded
  • ACOG 2000
  • ALTS 1976
  • Country
  • ACOG Canada
  • ALTS United States
  • Employees
  • ACOG N/A
  • ALTS N/A
  • Industry
  • ACOG
  • ALTS
  • Sector
  • ACOG
  • ALTS
  • Exchange
  • ACOG Nasdaq
  • ALTS NYSE
  • Market Cap
  • ACOG 80.3M
  • ALTS 159.4M
  • IPO Year
  • ACOG N/A
  • ALTS N/A
  • Fundamental
  • Price
  • ACOG $10.50
  • ALTS $7.13
  • Analyst Decision
  • ACOG Strong Buy
  • ALTS
  • Analyst Count
  • ACOG 1
  • ALTS 0
  • Target Price
  • ACOG $20.00
  • ALTS N/A
  • AVG Volume (30 Days)
  • ACOG 67.4K
  • ALTS 309.3K
  • Earning Date
  • ACOG 08-14-2025
  • ALTS 08-18-2025
  • Dividend Yield
  • ACOG N/A
  • ALTS N/A
  • EPS Growth
  • ACOG N/A
  • ALTS N/A
  • EPS
  • ACOG N/A
  • ALTS N/A
  • Revenue
  • ACOG $2,928,654.00
  • ALTS $18,046,000.00
  • Revenue This Year
  • ACOG N/A
  • ALTS $185.91
  • Revenue Next Year
  • ACOG N/A
  • ALTS $64.93
  • P/E Ratio
  • ACOG N/A
  • ALTS N/A
  • Revenue Growth
  • ACOG N/A
  • ALTS N/A
  • 52 Week Low
  • ACOG $3.75
  • ALTS $1.29
  • 52 Week High
  • ACOG $11.54
  • ALTS $10.95
  • Technical
  • Relative Strength Index (RSI)
  • ACOG N/A
  • ALTS 45.85
  • Support Level
  • ACOG N/A
  • ALTS $7.06
  • Resistance Level
  • ACOG N/A
  • ALTS $8.15
  • Average True Range (ATR)
  • ACOG 0.00
  • ALTS 0.86
  • MACD
  • ACOG 0.00
  • ALTS -0.14
  • Stochastic Oscillator
  • ACOG 0.00
  • ALTS 29.14

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About ALTS ALT5 SIGMA CORPORATION

ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.

Share on Social Networks: